St. Jude Falls on More Durata Concerns

By Avi Salzman

St. Jude Medical (STJ) is dealing with more fallout over its Durata leads today, after an FDA report about the leads indicated that the company’s “design verification activities were inadequate,” according to a Wall Street Journal article. Parts of the FDA report had been released last month, but with heavy redactions.

The leads connect defibrillators to the heart. St. Jude had to recall its older Riata leads last year because wires came through the insulation in some of them. The company has stood behind its Durata leads, but the new details are clearly shaking the Street’s confidence.

About Stocks To Watch

Earnings reports, corporate strategies and analyst insights are all part of what moves stocks, and they’re all covered by the Stocks to Watch blog. We also look at macro issues, investor sentiments and hidden trends that are affecting the market. Stocks to Watch gives you the full picture of the U.S. stock markets, all day long.

The blog is written by Ben Levisohn, a former stock trader who has covered financial markets for the Wall Street Journal, Bloomberg and BusinessWeek.